Letter to the editor: Safety and immunogenicity of a novel recombinant rabies vaccine

Anurag AgarwalDepartment of Pediatrics, Maulana Azad Medical College & Associated Hospitals, New Delhi, IndiaView further author information

Surendra Bahadur MathurDepartment of Pediatrics, Maulana Azad Medical College & Associated Hospitals, New Delhi, IndiaCorrespondence[email protected]

References

HS R, Khobragade A, Satapathy D, Gupta M, Kumar S, Bhomia V, V R, Desai M, Agrawal AD. Safety and immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: a randomized, comparator controlled, multicenter, phase III clinical study. Hum Vaccines Immunother. 2021;17(11):1–2. doi:10.1080/21645515.2021.1957413.
PubMed Web of Science ®Google Scholar
International Committee of Medical Journal Editors. Recommen- dations: defining the role of authors and contributors [Internet]. [accessed 2022 May 8]. https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html.
Google Scholar
World Health Organization. Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs, Annex 2, TRS No 941 [Internet]. [accessed 2022 May 8]. https://www.who.int/publications/m/item/inactivated-rabies-vaccine-for-human-use-annex-2-trs-no-941.
Google Scholar